Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
By Alex Philippidis, GEN Edge, Aug 10, 2026
Next 10 U.S. Biopharma Clusters
By Alex Philippidis, GEN, Aug 12, 2026
Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map
By Alex Philippidis, GEN Edge, Aug 5, 2026
COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID
GEN, Aug 5, 2026
Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained
By Alex Philippidis, GEN, Oct 5, 2020
Lessons from the COVID Crisis: An Interview with Peter Hotez
By Alex Philippidis, GEN Edge, Oct 19, 2022
By Alex Philippidis, GEN, March 2, 2020
Candida auris Persists in Hair Follicles, Hijacks Immune Signaling
GEN, August 10, 2026
The State of Biotech Summit
September 23, 2026
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
The State of Biologics Testing 2026
Charles River Laboratories and GEN, June 10, 2026
Subscribe to GEN’s newsletters
Produced with support from:
